STAT

Kennedy asks for feedback on new vaccine recommendation categories, how shots are tested.

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

Roche's Genentech will invest $750 million to double the size of its existing production facility in Oregon

Moderna's stunning surge and drop, AI in scientific writing, and more biotech news from The Readout

Prostate cancer therapy, Meta glasses in hospital settings, and more health news from Morning Rounds

Urologic oncologists who treat prostate cancer are split over the benefits of focal therapy compared to traditional surgery or radiation.

We continue to romanticize the symptoms of mental health problems, especially when we talk about achievement.

What you need to know about Heidi Overton, and Erica Schwartz's first speech to CDC staff.

Regeneron wins ultra-rare disease drug approval, a validating win for mRNA research, and more biotech news from The Readout

Heidi Overton's rise under Trump, inside a 5-year-old brain organoid, and other health news from Morning Rounds

A Regeneron drug for an ultra-rare disease that causes bone to grow where it shouldn't won U.S. regulatory approval, capping a three-decade effort

Between success with a pancreatic cancer drug and now success with an mRNA neoantigen vaccine, it has been a banner year for developing cancer therapies.

Capricor Therapeutics is trying to stave off FDA rejection of its cell therapy for Duchenne muscular dystrophy.

Several large health systems are rolling out AI chatbots to query patient records, saying they save time and increase diagnostic accuracy.

“Regulatory flexibility can be exercised in rare disease without sacrificing rigor,” writes Mindy Leffler, whose son has Duchenne muscular dystrophy.

Males make up about a third of the population struggling with eating disorders in the United States. While these conditions often start during the teen years, by some estimates, as…

Reducing protein intake could increase human longevity, researchers recently suggested. That's a bad idea, for several reasons, experts say.

“Washington has rediscovered faith as a delivery mechanism. The bigger opportunity is faith as a source of capital,” writes Dr. Alaa Murabit.

If she wins confirmation as FDA commissioner, Heidi Overton will face plenty of big challenges.